Unapproved stem cell therapies remains a top FDA enforcement priority | Hogan Lovells
Speaking Tuesday at the Food and Drug Law Institute (FDLI) Annual Conference, Mark Raza, FDA Chief Counsel, discussed the investigations priorities for FDA’s Office of the Chief Counsel...